Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26272847 | 0.90 | OPRD1 (0.42) | OPRD1OPRM1OPRK1RENACE | |
| SCHEMBL26272475 | 0.88 | OPRD1 (0.40) | OPRD1OPRM1OPRK1RENACE | |
| SCHEMBL26502139 | 0.87 | CTSL (0.53) | OPRD1OPRM1OPRK1CTSLCTSB | |
| SCHEMBL24406186 | 0.87 | CTSL (0.53) | OPRD1OPRM1OPRK1CTSLCTSB | |
| SCHEMBL26286461 | 0.87 | CTSL (0.53) | OPRD1OPRM1OPRK1CTSLCTSB | |
| SCHEMBL26272608 | 0.82 | OPRD1 (0.40) | OPRD1OPRM1OPRK1PSMB5ACE | |
| SCHEMBL26272782 | 0.81 | ACE (0.41) | OPRD1OPRM1OPRK1PSMB5ACE | |
| SCHEMBL26272706 | 0.81 | ACE (0.41) | OPRD1OPRM1OPRK1PSMB5ACE | |
| SCHEMBL31303638 | 0.80 | CTSS (0.53) | OPRD1OPRM1PSMB5ACECTSL | |
| SCHEMBL10688246 | 0.79 | QRFPR (0.47) | OPRD1OPRM1RENACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SYSTIMMUNE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SLC7A1, CD44, DCLRE1A | OPRD1 3924/4885OPRM1 3807/4885OPRK1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.